Danijela Mandic
Overview
Explore the profile of Danijela Mandic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mandic D, Nezic L, Amdzic L, Vojinovic N, Gajanin R, Popovic M, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627134
Background: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment resistance to the first-line R-CHOP regimen. ATP binding cassette (ABC) transporters and survivin might play a role...
2.
Nezic L, Amidzic L, Skrbic R, Gajanin R, Mandic D, Dumanovic J, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269738
Disruption of the alveolar−endothelial barrier caused by inflammation leads to the progression of septic acute lung injury (ALI). In the present study, we investigated the beneficial effects of simvastatin on...
3.
Collins G, Eyre T, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, et al.
Hemasphere
. 2021 Dec;
5(11):e656.
PMID: 34901759
Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the response rate...
4.
Kuruc Poje D, Kifer D, Huys I, Miranda J, Jenzer H, Miljkovic N, et al.
BMC Health Serv Res
. 2021 Jul;
21(1):689.
PMID: 34253212
Background: It is known that drug shortages represent a major challenge for all stakeholders involved in the process, but there is little evidence regarding insights into patients' awareness and perspectives....
5.
Mandic D, Nezic L, Skrbic R
Med Pregl
. 2014 Jul;
67(5-6):181-4.
PMID: 25033579
Introduction: Hyperkalemia secondary to beta-adrenergic receptor blockade occurs in 1-5% of patients and is likely to develop with non-cardio-selective beta-blockers. Case Report: We have described hyperkalemia in a patient with...